The overall role includes to; Secure the clinical development strategy and plan to deliver the growth targets set by HND management. Formulate and drive execution of the clinical development program. Act as medical and clinical reference for innovation in probiotics and therapeutic bacteria.

Director, Global Molecular Pharmacology, H. Lundbeck A/S, Denmark: Global Molecular Pharmacology was a multidisciplinary unit, who covered all aspect of in vitro pharmacology for Neuroscience drug discovery projects (CNS disorders e.g. Alzheimer’s and Parkinson’s Disease, mood disorders, schizophrenia, and other CNS syndromes). We were located in Copenhagen (Denmark) and New Jersey (USA), but collaborated globally with CRO in USA, Europe and China.Global Molecular Pharmacology was specialized in cellular and biochemical pharmacology including in vitro assay development, laboratory automation, high and medium throughput screening, advanced mechanism of action assessment for target engagement and information technology. We focused on receptor pharmacology, enzymology, ion channel and GPCRs pharmacology, pharmacological characterization of antibody- antigen interactions and immune and inflammatory assays/signaling. I was responsible for the global delivery of molecular pharmacology and I had direct line-management responsibility for the Copenhagen unit. This included responsibility for internal and external budgets, planning of timelines, staffing and scientific deliveries. I provided strategic leadership for molecular pharmacology and input to strategic boards.

Project Coordinator of The Genome Denmark project, University of Copenhagen; The GenomeDenmark project aimed to provide "The Danish Platform for Large-scale Sequencing and Bioinformatic” and was a collaboration between public and private institutions; Copenhagen University, Aarhus University, Aalborg University, Capital Region of Copenhagen, Danish Technical University, Bavarian Nordic and BGI-Europe. The project plan included two sub-projects: Cancer & Pathogens project and The PanGenome project, with a joint budget of 23 million Eur. I was responsible for the overall management of the project, its business plan, the budget, interaction between partners and contact to the founder; The Danish National Advanced Technology and reported to the board of directors. I provided to input to project plans and ensured timely deliveries as well as public communication and network.

At Astra Zeneca, I headed a team of Scientists and Project Managers responsible for managing research projects within the disease area Respiratory and Inflammation. The main focus for the team was generation of new project, covering identification and validation of targets for novel therapeutic species, being small molecules, protein/antibodies or siRNA’s. All project was validated in human material in cell culture and histologically.

I was responsible for the establishment and leadership of an efficient section for automated screening at LEO Pharma. The section was involved in all phases of early drug discovery. This included target identification and validation, assay development, high and medium throughput screening, high content screening, hit to lead, lead optimization drug candidate identification.

During the post doc, I worked on a program aiming at identification of components which release GLP-1 from L-cells, ultimately leading to therapy for diabetes.

The PhD program was focused on the study of L-cell biology and the biochemistry of GLP-1 release.

Master thesis - Biological effects of growth hormone